Thus increasing PDCD4 levels through pharmacological manipulation of miR-21 could represent a novel therapeutic strategy in the treatment of CRC, as an alternative to COX-2/PGE2 blockade in CRC. This evidence concerns the gene PDCD4 and colorectal carcinoma.